Andrea Lobo,  —

Switching from maintenance therapeutic plasma exchange (TPE) to Vyvgart (efgartigimod) appeared to be well tolerated and effective for people with myasthenia gravis (MG), a short report suggests. “The good clinical response of this patient cohort, together with greater accessibility and convenience of infusion-based therapy, are notable advantages…

Cour Pharmaceuticals announced that it has raised $105 million in Series A financing to advance its investigational therapy, CNP-106, into a Phase 1b/2a clinical trial as a possible treatment of myasthenia gravis (MG). A company request for clinical testing of CNP-106 was cleared by the U.S.

Despite treatment, people with myasthenia gravis (MG) in the U.S. continue to experience exacerbations — episodes of disease worsening that may require urgent treatment and hospitalization — that carry high clinical and economic costs. That’s according to a large retrospective analysis of claims data for patients with employer-based commercial…

High levels of serum fibrinogen were found to be a sensitive and specific biomarker to identify people with myasthenia gravis (MG), according to a recent study. Fibrinogen is a plasma protein that participates in blood clotting and is usually not present in the serum. In MG patients, residual fibrinogen…

Health Canada has approved Vyvgart (efgartigimod alfa-fcab) to treat adults with generalized myasthenia gravis (gMG) who are positive for antibodies targeting the acetylcholine receptor (AChR), the most common target of MG-causing antibodies. The approval is based on positive data from the Phase 3 ADAPT clinical trial (NCT03669588),…

Folia Health is expanding the use of its smartphone app for gathering self-reported patient health data to people with myasthenia gravis (MG) and other neurological conditions. Patients’ daily experiences will contribute to obtaining comprehensive data on disease progression and treatment response, which are expected to contribute to improving…

Pregnant women with myasthenia gravis (MG) are particularly susceptible to severe disease-related complications, usually caused by generalized muscle weakness, which can put the mother and child at risk, according to a recent review study. Newborns should also be monitored for symptoms of transient neonatal MG, a form of…

Patterns of facial weakness can be quantified with facial recognition software and computer models and used to diagnose and monitor myasthenia gravis (MG), a study finds. “This study delivers a ‘proof of concept’ for a [deep learning] model that can distinguish MG from [healthy controls] and classifies disease…

Composition of the fungal species present in the gut — known as the fungal gut microbiota — does not differ significantly between people with myasthenia gravis (MG) and those with other neurological disorders or healthy people. That’s according to an analysis of the fungal gut microbiota of participants in…

Ad Scientiam has launched a program to develop and validate new digital biomarkers for self-assessing patients with generalized myasthenia gravis (gMG). The launch was announced on Rare Disease Day, Feb. 28, and is supported by Alexion, AstraZeneca Rare Disease. “Easy-to-use digital tools have the potential to generate reliable…